Greenwich Lifesciences Inc (NASDAQ: GLSI) — Company Overview, News & Financial Data
Greenwich Lifesciences develops therapies for breast cancer, focusing on immunotherapy to improve patient quality of life.
Greenwich Lifesciences Inc
Greenwich Lifesciences (NASDAQ:GLSI) is a biopharmaceutical enterprise focused on the development and commercialization of therapeutics for breast cancer patients. The core of its operations lies in advancing GP2, an immunotherapy designed to prevent the recurrence of breast cancer following surgery. With a clear objective to enhance survival rates and quality of life for breast cancer sufferers, the company leverages cutting-edge scientific research to push the boundaries of treatment possibilities. Greenwich Lifesciences is dedicated to bringing novel, life-saving therapies to market, aiming to transform the landscape of cancer care for women worldwide.
Snapshot
Operations
Products and/or services of Greenwich Lifesciences Inc
- GP2 is a novel immunotherapy for preventing breast cancer recurrence.
- Research into immunotherapies targeting various cancer types.
- Development of precision medicine techniques for cancer treatment.
- Collaboration with academic and research institutions to advance cancer immunotherapy studies.
- Involvement in clinical trials to test the efficacy and safety of new cancer treatments.
- Providing educational resources and support for cancer patients and healthcare professionals.
Greenwich Lifesciences Inc executive team
- Mr. Snehal S. PatelCEO, CFO & Director
- Mr. Eric RotheFounder & Independent Director
- Dr. Frank Joseph Daugherty M.D.Chief Medical Officer & Director
- Dr. Jaye L. Thompson Ph.D.Vice President Clinical & Regulatory Affairs
- Dr. Christine T. Fischette Ph.D.VP of Business Development